Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of BBV154 Booster
NCT05567471Phase 3Completed
- Sponsor
- Bharat Biotech
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iNCOVACC in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Bharat Biotech. Primary endpoints: Geometric Mean Titres 1, Geometric Mean Titres 2 at Day 28 and 1 more. Started Feb 2022; status: completed.
02
Drugs
iNCOVACC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05567471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567471.